MAPS Public Benefit Corporation announced on 12 December 2023 that it submitted a new drug application (NDA) to the FDA for MDMA to be used in mental health therapy (MAPS Public Benefit Corp., Drug Bank - Midomafetamine, FDA - Drug Approval Process). The type of approval (e.g., Standard, Accelerated) is immaterial (FDA - Development & Approval Process). For the purposes of this question, any rescheduling of MDMA by the Drug Enforcement Administration is immaterial.

Confused? Check our FAQ or ask us for help. To learn more about Good Judgment and Superforecasting, click here.

To learn more about how you can become a Superforecaster, see here. For other posts from our Insights blog, click here.